Carvana stock closes higher as CVNA sets Feb. 18 earnings date; Barclays lifts target to $530
22 January 2026
1 min read

Carvana stock closes higher as CVNA sets Feb. 18 earnings date; Barclays lifts target to $530

NEW YORK, Jan 21, 2026, 20:04 EST — The market has closed for the day.

  • Carvana shares ended the day 2.9% higher at $455.02, then ticked up another 0.4% in late after-hours trading
  • Company scheduled fourth-quarter and full-year results for Feb. 18, with a call at 5:30 p.m. ET
  • Barclays boosted its price target to $530 while maintaining an Overweight rating

Carvana Co shares ended Wednesday’s session 2.9% higher, closing at $455.02 on volume of roughly 3.49 million. The online used-car seller remained within a narrow range toward the close. In after-hours trading, the stock ticked up 0.4% to $456.98. 1

This move is crucial as Carvana approaches its upcoming earnings with raised expectations. Traders will be keen to see if the recent rally sustains through Thursday’s session or if the stock falls back into the volatile swings it experienced earlier this month.

The upcoming earnings report stands as the main catalyst, with few other events lined up soon. This often draws both long-only investors and fast money into the same trade, creating a volatile mix.

Carvana announced it will release its fourth-quarter and full-year 2025 results after markets close on Wednesday, Feb. 18. The company’s management team will follow up with a conference call and webcast at 5:30 p.m. ET. 2

Barclays analyst John Babcock boosted Carvana’s price target to $530 from $465, maintaining an Overweight rating. He noted that while the firm trimmed estimates for the auto retail sector due to “soft” unit pressures, “trade checks suggest the used vehicle market has good momentum.” 3

A price target reflects a broker’s forecast for a stock’s potential trading range, usually within the next 12 months. When analysts say “overweight,” they mean the stock is expected to outperform its peers, though it’s not a promise.

Carvana’s shares have swung from a low of $148.25 to a high of $485.33 in the last 52 weeks, sitting roughly 6% shy of that peak despite Wednesday’s rally. The S&P 500 climbed 1.16% on the session, boosting risk appetite broadly. 4

The next big check-in is the Feb. 18 report. Investors will zero in on unit sales, per-vehicle profit margins, and management’s outlook on demand as 2026 approaches. Expect close scrutiny of any comments on funding costs and credit trends, since auto retail remains highly vulnerable to borrowing expenses.

The downside remains clear. Should used-car prices drop or financing tighten, margins could shrink quickly — and with the stock hovering near its yearly high, even a slight miss could trigger a sharp sell-off.

Traders will be eyeing if Wednesday’s gains hold through Thursday and into next week, along with any fresh target adjustments from brokers in the auto retail sector. Carvana’s next key date is Feb. 18, when it reports earnings after the close and fields questions on the call.

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
KLA (KLAC) stock rebounds to $1,520 as analysts hike targets ahead of earnings
Previous Story

KLA (KLAC) stock rebounds to $1,520 as analysts hike targets ahead of earnings

Bank of America stock: BAC holds near $52 after $1B employee stock award as credit-card rate cap returns to focus
Next Story

Bank of America stock: BAC holds near $52 after $1B employee stock award as credit-card rate cap returns to focus

Go toTop